Analyst Price Targets — BRVE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 31, 2026 10:13 am | Olivia Brayer Saunders | Cantor Fitzgerald | $40.00 | $27.44 | TheFly | Braveheart Bio initiated with an Overweight at Cantor Fitzgerald |
| August 31, 2026 9:00 am | — | Jefferies | $48.00 | $27.44 | TheFly | Braveheart Bio initiated with a Buy at Jefferies |
| August 31, 2026 8:58 am | James Condulis | Stifel Nicolaus | $45.00 | $27.44 | TheFly | Braveheart Bio initiated with a Buy at Stifel |
| August 31, 2026 8:32 am | — | Goldman Sachs | $48.00 | $27.44 | TheFly | Braveheart Bio initiated with a Buy at Goldman Sachs |
Latest News for BRVE
SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY.
The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.
The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this acquisition.
Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.
Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) Director David Charles Lubner purchased 55,555 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, with a total value of $999,990.00. Following the acquisition, the director directly owned 55,555 shares in the company,
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BRVE.
U.S. House Trading
No House trades found for BRVE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.